Overview
Quanta Therapeutics develops oral, allosteric small molecule inhibitors targeting undruggable RAS mutations like KRAS G12D and G12V for RAS-driven cancers, including pancreatic, colorectal, lung, and endometrial types. Their Phase 1 pipeline includes QTX3034 (G12D-preferring multi-KRAS), QTX3046 (G12D-selective), and QTX3544 (G12V-preferring multi-KRAS), with CNS-penetrant properties and preclinical proof-of-concept. The company leverages Second Harmonic Generation (SHG) technology for protein conformation detection and has sites in South San Francisco, CA, and Radnor, PA.
Frequently asked questions
- What are Quanta Therapeutics' key capabilities in RAS-targeted therapies?
- Quanta develops allosteric small molecules using SHG technology to modulate RAS signaling complexes, targeting KRAS G12D and G12V mutations with oral, CNS-penetrant inhibitors in Phase 1 trials.
- What is the regulatory status of Quanta's pipeline programs?
- QTX3034, QTX3046, and QTX3544 are in Phase 1 clinical trials for KRAS-mutant solid tumors, with QTX3034 advancing to dose expansion cohorts.
- Where are Quanta Therapeutics' operations located?
- Headquartered in South San Francisco, CA, with an additional site in Radnor, PA.